Pier Capital, LLC Tg Therapeutics, Inc. Transaction History

Pier Capital, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$8.36 - $26.5 $1.32 Million - $4.2 Million	158,391 Added 67.6%	392,709 $3.28 Million
Q2 2023 Aug 14, 2023	BUY	$15.48 - $35.0 $13,096 - $29,610	846 Added 0.36%	234,318 $5.82 Million
Q1 2023 May 10, 2023	BUY	$10.23 - $19.34 $2.39 Million - $4.52 Million	233,472 New	233,472 $3.51 Million
Q3 2021 Nov 10, 2021	SELL	$21.78 - $40.45 $6.11 Million - $11.3 Million	-280,486 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$32.5 - $48.96 $884,487 - $1.33 Million	27,215 Added 10.75%	280,486 $10.9 Million
Q1 2021 May 13, 2021	BUY	$41.61 - $54.3 $4.53 Million - $5.91 Million	108,857 Added 75.38%	253,271 $12.2 Million
Q4 2020 Feb 16, 2021	SELL	$25.27 - $54.9 $3.14 Million - $6.83 Million	-124,390 Reduced 46.28%	144,414 $7.51 Million
Q3 2020 Nov 13, 2020	BUY	$18.49 - $27.24 $4.97 Million - $7.32 Million	268,804 New	268,804 $7.19 Million

345

87.6M

2.35M

1.7M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.86B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Pier Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Pier Capital, LLC with notifications on news.